Skip to Main Content

Author Details

Christina Yau
University of California San Francisco
2005
100
38
Nevan J Krogan (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36689092Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study.Breast Cancer Res Treat2023
37029329Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.Breast Cancer Res Treat2023
37146605Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.Cancer Cell2023
37397981Impact of Body Mass Index on Pathological Response after Neoadjuvant Chemotherapy: Results from the I-SPY 2 trial.Res Sq2023
36811873Prognostic Significance of Residual Ductal Carcinoma In Situ After Complete Response of Invasive Breast Cancer to Neoadjuvant Therapy-Reply.JAMA Surg2023
37384294Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.Front Oncol2023
37188791Development and testing of a polygenic risk score for breast cancer aggressiveness.NPJ Precis Oncol2023
36689092Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study.Breast Cancer Res Treat2023
37188791Development and testing of a polygenic risk score for breast cancer aggressiveness.NPJ Precis Oncol2023
37384294Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.Front Oncol2023
37146605Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.Cancer Cell2023
37397981Impact of Body Mass Index on Pathological Response after Neoadjuvant Chemotherapy: Results from the I-SPY 2 trial.Res Sq2023
37029329Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.Breast Cancer Res Treat2023
36811873Prognostic Significance of Residual Ductal Carcinoma In Situ After Complete Response of Invasive Breast Cancer to Neoadjuvant Therapy-Reply.JAMA Surg2023
34902335Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.Lancet Oncol2022
35513244Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.Ann Oncol2022
35623341Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.Cancer Cell2022
36069821Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.JAMA Surg2022
35862873Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.J Clin Oncol2022
35789445Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer.Breast Cancer Res Treat2022
36414627Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.Nat Commun2022
36456573Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.NPJ Breast Cancer2022
35240097Survivorship after neoadjuvant chemotherapy - Authors' reply.Lancet Oncol2022
34902335Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.Lancet Oncol2022
35179782Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature.Int J Cancer2022
35789445Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer.Breast Cancer Res Treat2022
35862873Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.J Clin Oncol2022
35623341Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.Cancer Cell2022
35513244Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.Ann Oncol2022
36456573Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.NPJ Breast Cancer2022
36414627Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.Nat Commun2022
36069821Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.JAMA Surg2022
35179782Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature.Int J Cancer2022
35240097Survivorship after neoadjuvant chemotherapy - Authors' reply.Lancet Oncol2022
34190995Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.JAMA Netw Open2021
33913053Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer.Breast Cancer Res Treat2021
33626341Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway.Cell Rep2021
33617937Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.Ann Oncol2021
34143979Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.Cancer Cell2021
34095775PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial.JAMIA Open2021
33767190Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk.NPJ Breast Cancer2021
33982016Integrative modeling identifies genetic ancestry-associated molecular correlates in human cancer.STAR Protoc2021
34190995Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.JAMA Netw Open2021
34741023Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trial.Nat Commun2021
34741021RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer.Nat Commun2021
34611148Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.NPJ Breast Cancer2021
34427465Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.Radiology2021
34529196The WISDOM study: a new approach to screening can and should be tested.Breast Cancer Res Treat2021
34529000Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.JAMA Oncol2021
33767190Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk.NPJ Breast Cancer2021
  • 1 - 50 of 200

Recommended Authors

Kevin Punie
Leuven Cancer Institute and University Hospitals Leuven
Career Start Year 2015
Number of shared co-authors 11
Leen Slaets
50148Janssen Pharmaceutica NV
Career Start Year 2014
Number of shared co-authors 4
Martin Sj??str??m
University of California-San Francisco
Career Start Year 2013
Number of shared co-authors 1
Tammy Piper
University of Edinburgh
Career Start Year 2012
Number of shared co-authors 4
Konstantinos Tryfonidis
Merck & Co., Inc.
Career Start Year 2011
Number of shared co-authors 4
Hans Kristian Moen Vollan
F Hoffmann-La Roche Ltd
Career Start Year 2010
Number of shared co-authors 5
Carmen Criscitiello
University of Milano
Career Start Year 2008
Number of shared co-authors 0
Melanie Spears
Ontario Institute for Cancer Research
Career Start Year 2008
Number of shared co-authors 1
Bora Lim
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 4
Samuel Leung
University of British Columbia
Career Start Year 2007
Number of shared co-authors 14
Hannah Y Wen
Memorial Sloan Kettering Cancer Center
Career Start Year 2007
Number of shared co-authors 4
Catherine M Kelly
Mater Misericordiae University Hospital
Career Start Year 2006
Number of shared co-authors 3
Aditya Bardia
Massachusetts General Hospital Cancer Center
Career Start Year 2004
Number of shared co-authors 2
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 3
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 6
Nicola Fusco
IEO European Institute of Oncology IRCCS
Career Start Year 2002
Number of shared co-authors 1
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 58
Peter A Fasching
Otto-Friedrich-University Bamberg
Career Start Year 2002
Number of shared co-authors 24
Joshua Chuck Harrell
Virginia Commonwealth University
Career Start Year 2002
Number of shared co-authors 1
Britta Weigelt
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 14
Ingrid A Mayer
Vanderbilt University Medical Center
Career Start Year 2000
Number of shared co-authors 4
Fatima Cardoso
Champalimaud Clinical Center/Champalimaud Foundation
Career Start Year 2000
Number of shared co-authors 11
Massimo Cristofanilli
Weill Cornell School of Medicine
Career Start Year 1998
Number of shared co-authors 11
Ingrid Hedenfalk
Lund University and Skane University Hospital
Career Start Year 1997
Number of shared co-authors 9
Giuseppe Curigliano
University of Milan
Career Start Year 1996
Number of shared co-authors 3
Naoto T Ueno
Cancer Research Center of Hawaii: University of Hawai'i Cancer Center.
Career Start Year 1995
Number of shared co-authors 14
Steven J Isakoff
Massachusetts General Hospital
Career Start Year 1995
Number of shared co-authors 10
Daniel Rea
Institute of Cancer and Genomic Sciences, The University of Birmingham
Career Start Year 1993
Number of shared co-authors 3
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Career Start Year 1990
Number of shared co-authors 41
John W M Martens
Erasmus Medical Center (MC) Cancer Institute
Career Start Year 1989
Number of shared co-authors 21

Collaborators

Laura J Van't Veer
University of California San Francisco
Co-authored papers 46
Christopher C Benz
Buck Institute for Research on Aging
Co-authored papers 36
Denise M Wolf
University of California San Francisco
Co-authored papers 28
Donald A Berry
MD Anderson Cancer Center
Co-authored papers 22
William F Symmans
Co-authored papers 20
Minetta C Liu
Co-authored papers 15
Claudine Isaacs
Co-authored papers 14
Rita Nanda
Co-authored papers 14
Judy C Boughey
Mayo Clinic
Co-authored papers 14
Katherine A Hoadley
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Co-authored papers 12
Andrew D Cherniack
Dana-Farber Cancer Institute
Co-authored papers 12
Amy G Robertson
Present address: Dxige Research Inc.
Co-authored papers 11
Lajos Pusztai
Co-authored papers 11
Richard B Schwab
Department of Medicine and Moores Cancer Center, University of California San Diego
Co-authored papers 10
Emanuel F Petricoin
Center for Applied Proteomics and Molecular Medicine, George Mason University
Co-authored papers 9
Melissa Paoloni
Center for Cancer Research, National Cancer Institute
Co-authored papers 8
Teresa Helsten
Moores Cancer Center, University of California San Diego
Co-authored papers 8
Rehan Akbani
The University of Texas MD Anderson Cancer Center
Co-authored papers 8
Peter W Laird
Van Andel Institute
Co-authored papers 8
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 7
Hui Shen
Van Andel Institute
Co-authored papers 7
Scott M Berry
University of Kansas Medical Center
Co-authored papers 7
Joshua M Stuart
University of California at Santa Cruz
Co-authored papers 6
Alexander J Lazar
The University of Texas MD Anderson Cancer Center
Co-authored papers 5
Charles M Perou
Co-authored papers 5
Yuexin Liu
The University of Texas MD Anderson Cancer Center
Co-authored papers 5
John N Weinstein
The University of Texas MD Anderson Cancer Center
Co-authored papers 5
Cyriac Kandoth
University of California los angeles
Co-authored papers 5
Lisa A Carey
Co-authored papers 5
Jean Claude Zenklusen
National Cancer Institute
Co-authored papers 4
Release 1.2